Commercial preterm formulas with glucose polymers and reduced lactose show higher necrotizing enterocolitis rates than breast milk

Photo by Gabriel Tovar / Unsplash

Frontiers in Medicine Published June 4, 2026 Medically reviewed June 4, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note higher necrotizing enterocolitis rates with commercial preterm formulas versus breast milk.

This comprehensive review evaluates the relationship between commercial preterm formulas containing glucose polymers and reduced lactose content versus breast milk in preterm infants. The primary focus is the risk of developing necrotizing enterocolitis. The analysis indicates that higher rates of necrotizing enterocolitis occur with preterm formulas compared to breast milk. Specific effect sizes or absolute numbers were not reported in the source material. The review does not provide data on adverse events or tolerability. The authors note that the mechanisms by which preterm formulas increase the risk of necrotizing enterocolitis have not been fully elucidated. Funding sources and potential conflicts of interest were not reported. The review addresses the causal relationship between these formulas and necrotizing enterocolitis while cautioning against overstating the pathogenic agent. The authors suggest a complementary research agenda to identify additional protective elements of breast milk and additional nocive elements of preterm formulas. This information is relevant for clinicians managing nutrition in the neonatal intensive care setting.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

After more than 70 years of research, necrotizing enterocolitis (NEC) remains the most serious gastrointestinal disease among preterm infants and a leading cause of mortality, morbidity, and disability. Although causes of NEC are multifactorial, this contribution reviews the causal relationship between commercial preterm formulas (PTF) and NEC. The responses of the immature preterm intestine to PTF and the relationship to NEC have been extensively investigated using animal models and in human studies, but the mechanisms by which PTF increases the risk of NEC have not been fully elucidated. Two categories of risk factors may contribute to the higher rates of NEC with PTF compared to breast milk: (1) protective elements in breast milk are missing from PTF and (2) specific ingredients of PTF increase NEC risk. Our comprehensive review of animal studies and clinical trials highlights at least one substance in each category. The principle carbohydrate in breast milk is non-nocive lactose; in PTF, 50%–60% of the lactose is replaced by glucose polymers, which are not present in breast milk, and represent a pathogenic agent. We advocate a complementary research agenda to identify additional protective elements of breast milk (besides lactose) that could be added to PTF and additional nocive elements of PTF (besides glucose polymers) that could be removed to reduce the risk of NEC.